Hematology Clinical Development Lead

Scorpion Therapeutics; Watertown (MA); Hybrid; USD 180,000 - 240,000; Full time

Job summary

Scorpion Therapeutics in Watertown, MA is seeking a Medical Director, Clinical Development to oversee hematology and iron metabolism programs, with responsibility for trial design, medical oversight, and strategic development to advance the company’s pipeline.

You will lead trial planning, medical monitoring, data interpretation, and regulatory document support, collaborating with Clinical Science, Operations, Regulatory, and Medical Affairs, and engaging external investigators and key opinion

Qualifications

• MD, DO, or equivalent; board certification or eligibility in Hematology, Oncology, or Internal Medicine preferred; 3–5+ years experience in clinical research or development with trial oversight, medical monitoring, or study physician roles.
• Strong knowledge of trial methodology, biostatistics, and safety data interpretation.
• Demonstrated ability to collaborate across disciplines and communicate complex data effectively.

Responsibilities

• Clinical trial planning and medical oversight across programs.
• Data interpretation and regulatory document support.
• Cross-functional collaboration with Clinical Science, Operations, Regulatory, and Medical Affairs.
• External engagement with investigators and KOLs; scientific communications.

Skills

Trial oversight

Biostatistics

Medical monitoring

Cross-functional collaboration

Data interpretation

Education

MD/DO

Board certification eligible (Hem/Onc/IM)

Job description

Scorpion Therapeutics in Watertown, MA is seeking a Medical Director, Clinical Development to oversee hematology and iron metabolism programs, with responsibility for trial design, medical oversight, and strategic development to advance the company’s pipeline.

You will lead trial planning, medical monitoring, data interpretation, and regulatory document support, collaborating with Clinical Science, Operations, Regulatory, and Medical Affairs, and engaging external investigators and key opinion